These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 33746521)

  • 1. Mifepristone as Bridge or Adjunct Therapy in the Management of Challenging Cushing Disease Cases.
    Chang AY; Mirfakhraee S; King EE; Mercado JU; Donegan DM; Yuen KC
    Clin Med Insights Endocrinol Diabetes; 2021; 14():1179551421994102. PubMed ID: 33746521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations.
    Brown DR; East HE; Eilerman BS; Gordon MB; King EE; Knecht LA; Salke B; Samson SL; Yuen KCJ; Yau H
    Clin Diabetes Endocrinol; 2020 Oct; 6(1):18. PubMed ID: 33292727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful long-term treatment of Cushing disease with mifepristone (RU486).
    Basina M; Liu H; Hoffman AR; Feldman D
    Endocr Pract; 2012; 18(5):e114-20. PubMed ID: 22441000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and Radiological Changes in Liver Steatosis Following Mifepristone Treatment in Patients With Hypercortisolism.
    Parker JC; Moraitis AG; Belanoff JK
    AACE Clin Case Rep; 2022; 8(1):25-29. PubMed ID: 35097198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mifepristone Increases Thyroid Hormone Requirements in Patients With Central Hypothyroidism: A Multicenter Study.
    Guarda FJ; Findling J; Yuen KCJ; Fleseriu M; Nachtigall LB
    J Endocr Soc; 2019 Sep; 3(9):1707-1714. PubMed ID: 31528830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mifepristone Treatment in Four Cases of Primary Bilateral Macronodular Adrenal Hyperplasia (BMAH).
    Cohan P; East HE; Galati SJ; Mercado JU; Lim PJ; Lamerson M; Smith JJ; Peters AL; Yuen KCJ
    J Clin Endocrinol Metab; 2019 Dec; 104(12):6279-6290. PubMed ID: 31112270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.
    Fleseriu M; Molitch ME; Gross C; Schteingart DE; Vaughan TB; Biller BM
    Endocr Pract; 2013; 19(2):313-26. PubMed ID: 23337135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mifepristone Treatment of Cushing's Syndrome in a Pediatric Patient.
    Banerjee RR; Marina N; Katznelson L; Feldman BJ
    Pediatrics; 2015 Nov; 136(5):e1377-81. PubMed ID: 26459648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Merits and pitfalls of mifepristone in Cushing's syndrome.
    Castinetti F; Fassnacht M; Johanssen S; Terzolo M; Bouchard P; Chanson P; Do Cao C; Morange I; Picó A; Ouzounian S; Young J; Hahner S; Brue T; Allolio B; Conte-Devolx B
    Eur J Endocrinol; 2009 Jun; 160(6):1003-10. PubMed ID: 19289534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mifepristone for management of Cushing's syndrome.
    Morgan FH; Laufgraben MJ
    Pharmacotherapy; 2013 Mar; 33(3):319-29. PubMed ID: 23436494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone.
    Castinetti F; Conte-Devolx B; Brue T
    Neuroendocrinology; 2010; 92 Suppl 1():125-30. PubMed ID: 20829633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.
    Fleseriu M; Biller BM; Findling JW; Molitch ME; Schteingart DE; Gross C;
    J Clin Endocrinol Metab; 2012 Jun; 97(6):2039-49. PubMed ID: 22466348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of mifepristone in the treatment of Cushing's syndrome.
    Carroll T; Findling JW
    Drugs Today (Barc); 2012 Aug; 48(8):509-18. PubMed ID: 22916338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained weight loss in patients treated with mifepristone for Cushing's syndrome: a follow-up analysis of the SEISMIC study and long-term extension.
    Fein HG; Vaughan TB; Kushner H; Cram D; Nguyen D
    BMC Endocr Disord; 2015 Oct; 15():63. PubMed ID: 26507877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mifepristone (RU 486) in Cushing's syndrome.
    Johanssen S; Allolio B
    Eur J Endocrinol; 2007 Nov; 157(5):561-9. PubMed ID: 17984235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AACE/ACE Disease State Clinical Review: Medical Management of Cushing Disease.
    Hamrahian AH; Yuen KC; Hoffman AR;
    Endocr Pract; 2014 Jul; 20(7):746-57. PubMed ID: 25057099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. POSTSURGICAL RECURRENT CUSHING DISEASE: CLINICAL BENEFIT OF EARLY INTERVENTION IN PATIENTS WITH NORMAL URINARY FREE CORTISOL.
    Carroll TB; Javorsky BR; Findling JW
    Endocr Pract; 2016 Oct; 22(10):1216-1223. PubMed ID: 27409817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical Management of Cushing Disease.
    Tritos NA; Biller BMK
    Neurosurg Clin N Am; 2019 Oct; 30(4):499-508. PubMed ID: 31471057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome.
    Castinetti F; Brue T; Conte-Devolx B
    Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):295-9. PubMed ID: 22543346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mifepristone: treatment of Cushing's syndrome.
    Sartor O; Cutler GB
    Clin Obstet Gynecol; 1996 Jun; 39(2):506-10. PubMed ID: 8734015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.